Paper Details

  1. Home
  2. Paper Details

Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies.

Author: CurranDesmond, LecrenierNicolas, Mwakingwe-OmariAgnes, NaficyAbdi, PosiunieneInga

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

The recombinant zoster vaccine (RZV) is effective in preventing herpes zoster (HZ) in adults aged 50 years and older and in immunocompromised adults aged 18 years and older. The vaccine has a good safety profile and is effective against HZ complications such as post-herpetic neuralgia and HZ-related pain.
Paper Details　
Original Abstract of the Article :
Herpes zoster (HZ) is a debilitating vaccine-preventable disease. Impairment of cell-mediated immunity, as observed with aging and immunosuppressive disorders and therapies, increases risk. Recombinant zoster vaccine (RZV) is efficacious against HZ in adults aged ≥50 years in different settings, and...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653762/

データ提供：米国国立医学図書館（NLM）

Recombinant Zoster Vaccine: A Protective Oasis Against Herpes Zoster

Herpes zoster (HZ), commonly known as shingles, is a painful and debilitating viral infection that can leave lasting scars, like a desert storm ravaging the skin. This review examines the efficacy and safety of recombinant zoster vaccine (RZV) in both immunocompetent and immunocompromised adults, populations at higher risk for HZ. The researchers compiled data from multiple clinical studies to assess the vaccine's performance in different settings.

A Vaccine Oasis for Shingles Protection

The review highlights that RZV, like a life-giving oasis in the desert of HZ, provides significant protection against HZ in adults aged 50 years and older, as well as in immunocompromised adults aged 18 years and older. The vaccine has also demonstrated efficacy in reducing the severity of HZ complications, such as post-herpetic neuralgia, a chronic pain condition that can linger long after the rash has cleared.

Navigating the Desert of Shingles Risk

This review provides valuable insights for individuals seeking to protect themselves from HZ. RZV, with its proven efficacy and safety profile, offers a valuable tool for reducing the risk of this painful and debilitating condition. By embracing vaccination, we can create a protective oasis against the desert storm of HZ and safeguard our health.

Dr.Camel's Conclusion

The recombinant zoster vaccine (RZV) emerges as a protective oasis in the desert of herpes zoster (HZ). This review highlights its efficacy and safety, offering a beacon of hope for individuals seeking to reduce their risk of this painful and debilitating condition. Vaccination remains a crucial tool in our arsenal against HZ, allowing us to navigate the desert of shingles risk with greater confidence and peace of mind.

Date :
  1. Date Completed 2023-11-16
  2. Date Revised 2023-11-19
Further Info :

Pubmed ID

37965770

DOI: Digital Object Identifier

PMC10653762

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.